Paul Choi
Stock Analyst at Goldman Sachs
(3.76)
# 748
Out of 5,006 analysts
109
Total ratings
54.29%
Success rate
8.33%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $15.51 | +28.95% | 1 | Sep 25, 2025 | |
| EXEL Exelixis | Initiates: Buy | $47 | $40.17 | +17.02% | 1 | Sep 17, 2025 | |
| AMRN Amarin Corporation | Maintains: Sell | $7 → $12 | $20.00 | -40.00% | 9 | Jun 25, 2025 | |
| URGN UroGen Pharma | Maintains: Neutral | $16 → $3 | $16.96 | -82.31% | 4 | May 22, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $7 → $8 | $2.41 | +231.95% | 6 | May 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $5 | $11.31 | -55.79% | 10 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Neutral | $12 → $8 | $9.85 | -18.78% | 3 | May 2, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $60 → $52 | $39.50 | +31.66% | 2 | Apr 17, 2025 | |
| VIR Vir Biotechnology | Maintains: Buy | $28 → $21 | $5.78 | +263.64% | 8 | Apr 17, 2025 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $10.61 | +13.10% | 3 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $3.33 | -9.91% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $12 → $10 | $10.13 | -1.28% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $211.57 | +6.35% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $143 | $53.31 | +168.24% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $42 | $65.34 | -35.72% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $60.11 | -0.17% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $16.29 | +16.67% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $38.34 | -16.54% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $54.10 | -7.58% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.75 | +300.00% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $400 → $50 | $11.75 | +325.53% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.44 | +1,636.11% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $15.86 | +971.88% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $4.90 | +63.43% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $137.85 | -2.07% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $61.22 | +390.04% | 2 | Mar 30, 2020 |
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $15.51
Upside: +28.95%
Exelixis
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $40.17
Upside: +17.02%
Amarin Corporation
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $20.00
Upside: -40.00%
UroGen Pharma
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $16.96
Upside: -82.31%
Gossamer Bio
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $2.41
Upside: +231.95%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $11.31
Upside: -55.79%
Arvinas
May 2, 2025
Maintains: Neutral
Price Target: $12 → $8
Current: $9.85
Upside: -18.78%
Xenon Pharmaceuticals
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $39.50
Upside: +31.66%
Vir Biotechnology
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $5.78
Upside: +263.64%
REGENXBIO
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $10.61
Upside: +13.10%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $3.33
Upside: -9.91%
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $10.13
Upside: -1.28%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $211.57
Upside: +6.35%
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $53.31
Upside: +168.24%
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $65.34
Upside: -35.72%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $60.11
Upside: -0.17%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $16.29
Upside: +16.67%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $38.34
Upside: -16.54%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $54.10
Upside: -7.58%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.75
Upside: +300.00%
Jun 27, 2023
Maintains: Sell
Price Target: $400 → $50
Current: $11.75
Upside: +325.53%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.44
Upside: +1,636.11%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $15.86
Upside: +971.88%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $4.90
Upside: +63.43%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $137.85
Upside: -2.07%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $61.22
Upside: +390.04%